Epizyme (EPZM) Highlights Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate
Tweet Send to a Friend
Epizyme, Inc. (NASDAQ: EPZM) announced today new preclinical data from its novel G9a program for sickle cell disease (SCD). The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
